Skip to main content

ACCURAY INC

For the period ended Jun 30, 2025. Filed Aug 28, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Aug 28, 2025

ARAY$3.19-16.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Operations and Comprehensive Income (Loss)

(in thousands, except per share amounts)

Years Ended June 30,
20252024
Net revenue:
Products (a)$237,580$234,164
Services (b)220,925212,387
Total net revenue458,505446,551
Cost of revenue:
Cost of products162,569161,061
Cost of services148,969142,569
Total cost of revenue (c)311,538303,630
Gross profit146,967142,921
Operating expenses:
Research and development (d)47,94249,732
Selling and marketing43,31542,619
General and administrative47,87150,066
Total operating expenses139,128142,417
Income from operations7,839504
Income from equity method investment4,7141,838
Interest expense(12,954)(11,624)
Gain on extinguishment of debt1,475—
Loss from change in fair value of warrant liability(499)—
Other income (expense), net559(2,538)
Income (loss) before provision for income taxes1,134(11,820)
Provision for income taxes2,7253,725
Net loss$(1,591)$(15,545)
Net loss per share - basic and diluted$(0.02)$(0.16)
Weighted average common shares used in computing net loss per share:
Basic and diluted102,76898,272
Net loss$(1,591)$(15,545)
Foreign currency translation adjustment1,557(2,445)
Change in defined benefit pension obligation828(2,199)
Comprehensive income (loss)$794$(20,189)

(a)

Includes sales of products to the joint venture, an equity method investment, of$101,563 during the year ended June 30, 2025, and$77,497 during the year ended June 30, 2024. See Note 11.

(b)

Includes sales of services to the joint venture, an equity method investment, of$18,521 during the year ended June 30, 2025, and$15,039 during the year ended June 30, 2024. See Note 11.

(c)

Includes cost of revenue from sales to the joint venture, an equity method investment, of$74,421 during the year ended June 30, 2025, and$59,853 during the year ended June 30, 2024. See Note 11.

(d)

Includes charge backs to the joint venture, an equity method investment, related to research and development of$1,482 during the year ended June 30, 2025 and $942 during the year ended June 30, 2024.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.